Article
Repurposing Melatonin in dual-mode for Wilson disease therapy as a Copper Chelator and an antioxidant agent
2025-09-02
Abstract excerpt
Loss-of-function mutations in copper-ATPase ATP7B underlie Wilson disease (WD), a disorder characterized by hepatic copper accumulation and severe hepato-neuropathology. Existing chelation therapeutics remove excess copper but lack intrinsic antioxidant capacity and frequently cause systemic toxicity. Here we evaluate melatonin, an FDA-approved indoleamine with antioxidant and putative metal-chelating activity, as...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 1d884697-5a9a-5d1b-bd61-d11aff86cc5f
- DOI
- 10.1101/2025.08.30.673002
